Search hospitals > Pennsylvania > Bethlehem
Lehigh Valley Hospital - Muhlenberg
Claim this profileBethlehem, Pennsylvania 18017
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
261 reported clinical trials
8 medical researchers
Summary
Lehigh Valley Hospital - Muhlenberg is a medical facility located in Bethlehem, Pennsylvania. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Lehigh Valley Hospital - Muhlenberg is involved with conducting 261 clinical trials across 497 conditions. There are 8 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage III
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Tareq Al BaghdadiGenesys Hurley Cancer Institute8 years of reported clinical research
Expert in Cancer
Expert in Pancreatic Cancer
73 reported clinical trials
130 drugs studied
Christopher M. Reynolds, MDSaint Joseph Mercy Hospital2 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
51 reported clinical trials
104 drugs studied
Philip J. StellaSaint Joseph Mercy Hospital5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
38 reported clinical trials
89 drugs studied
Elie G. DibGenesys Hurley Cancer Institute6 years of reported clinical research
Studies Multiple Myeloma
Studies Breast Cancer
38 reported clinical trials
105 drugs studied
Clinical Trials running at Lehigh Valley Hospital - Muhlenberg
Lung Cancer
Bladder Cancer
Breast Cancer
Ovarian Cancer
Esophageal cancer
Cancer
Breast cancer
Kidney Cancer
Multiple Myeloma
Prostate Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting2 awards Phase 310 criteria
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting2 awards Phase 38 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Lehigh Valley Hospital - Muhlenberg?
Lehigh Valley Hospital - Muhlenberg is a medical facility located in Bethlehem, Pennsylvania. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Lehigh Valley Hospital - Muhlenberg is involved with conducting 261 clinical trials across 497 conditions. There are 8 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.